PRTA241220P5000
- 0.10
- 0.000.00%
Prothena Newsroom
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Top Premarket Decliners
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Prothena Corp Analyst Ratings
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $24
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
JMP Securities Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $83
Prothena's Strategic Advancements and Financial Strength Underpin Buy Rating
Express News | Prothena Corporation PLC: Expect FY2024 Net Cash Used in Operating & Investing Actives to Be $148 to $160 Mln
Prothena | 8-K: Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q3 Revenue $970,000
Prothena | 10-Q: Q3 2024 Earnings Report
Prothena Corp Q3 2024 GAAP EPS $(1.10) Beats $(1.18) Estimate, Sales $970.00K Miss $1.23M Estimate
Express News | Prothena Q3 Operating Expenses USD 67.483 Million
Press Release: Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Prothena 3Q Loss $59M >PRTA
Prothena 3Q Loss/Shr $1.10 >PRTA
Here Are the Major Earnings After the Close Today
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?